FDA announces real-time clinical trials, request for information
The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply reports and data to the agency during the approved clinical trials rather than at completion. The agency said it had already completed two proof-of-concept trials using RTCT reporting. As part of the announcement, the FDA issued a request for information on a proposed pilot program to assess AI’s impact on efficiency, speed and quality of decision-making in early phase clinical trials. The agency will accept comments, submitted through regulations.gov, for 30 days following publication in the Federal Register.
Related News Articles
Headline
The AHA Nov. 3 launched a new webpage, Artificial Intelligence Policy and Advocacy, featuring AHA policy letters, statements, fact sheets, news and other…
Chairperson's File
Leadership matters, especially during times of change and transformation in healthcare. That’s why I was pleased to sit down with Steve Walsh, who joined the…
Headline
The West Health Accelerator at the AHA’s Health Research & Educational Trust will host a virtual session Oct. 29 at 2:30 p.m. ET on how hospitals are…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…
Headline
The Agency for Healthcare Research and Quality Oct. 7 announced the launch of the Super Intelligence for Healthcare Improvement Initiative, a two-part…
Headline
An AHA blog published Oct. 5 responds to a Blue Cross Blue Shield Association report suggesting that hospitals’ use of artificial intelligence-enabled…